• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mepolizumab for severe eosinophilic asthma - A one-year real life Portuguese study.

作者信息

Brás R, Paulino M, Varandas C, Coutinho C, Silva M I, Limão R, Costa C, Alonso E, Pedro E, Mendes A

机构信息

Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

出版信息

Pulmonology. 2021 Nov-Dec;27(6):579-581. doi: 10.1016/j.pulmoe.2021.05.007. Epub 2021 Jul 1.

DOI:10.1016/j.pulmoe.2021.05.007
PMID:34219042
Abstract
摘要

相似文献

1
Mepolizumab for severe eosinophilic asthma - A one-year real life Portuguese study.美泊利单抗治疗重度嗜酸性粒细胞性哮喘——一项为期一年的葡萄牙真实病例研究。
Pulmonology. 2021 Nov-Dec;27(6):579-581. doi: 10.1016/j.pulmoe.2021.05.007. Epub 2021 Jul 1.
2
Mepolizumab for Treatment of Severe Eosinophilic Asthma: A 5-Year Real-World Experience.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘：5年真实世界经验
J Investig Allergol Clin Immunol. 2023 Jun 15;33(3):209-210. doi: 10.18176/jiaci.0898. Epub 2023 Feb 23.
3
Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.美泊利珠单抗附加疗法在重度嗜酸性粒细胞性哮喘真实世界队列中的应答率、有效性及安全性
J Asthma. 2021 May;58(5):651-658. doi: 10.1080/02770903.2020.1723623. Epub 2020 Feb 12.
4
Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘真实世界队列患者的疗效和安全性。
J Asthma. 2021 Jan;58(1):79-84. doi: 10.1080/02770903.2019.1658208. Epub 2019 Sep 3.
5
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.从奥马珠单抗转换为美泊利珠单抗：来自意大利南部的真实临床经验。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620929231. doi: 10.1177/1753466620929231.
6
Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘：希腊哮喘专科诊所 2 年随访结果：中期分析。
Int Arch Allergy Immunol. 2020;181(8):613-617. doi: 10.1159/000508559. Epub 2020 Jun 22.
7
Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.按年龄和哮喘发病年龄划分的可接受美泊利珠单抗治疗的重度哮喘患者比例。
J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2689-2696.e2. doi: 10.1016/j.jaip.2019.05.053. Epub 2019 Jun 13.
8
Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.严重的未控制的嗜酸性粒细胞性哮喘，在对美泊利珠单抗治疗无效后对贝那利珠单抗有反应。
Ann Allergy Asthma Immunol. 2019 Apr;122(4):431-433. doi: 10.1016/j.anai.2018.12.014. Epub 2018 Dec 19.
9
Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.皮下注射美泊利珠单抗治疗 6 至 11 岁严重嗜酸性粒细胞性哮喘儿童患者的疗效。
Pediatr Pulmonol. 2019 Dec;54(12):1957-1967. doi: 10.1002/ppul.24508. Epub 2019 Sep 9.
10
Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma.真实世界疗效及对美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘的“超级应答者”特征
Chest. 2020 Aug;158(2):491-500. doi: 10.1016/j.chest.2020.03.042. Epub 2020 Apr 8.

引用本文的文献

1
Effectiveness of anti-IL-5/5Rα biologics in severe asthma in real-world studies: a systematic review and meta-analysis.抗IL-5/5Rα生物制剂在真实世界研究中治疗重度哮喘的有效性：一项系统评价和荟萃分析
ERJ Open Res. 2025 Mar 24;11(2). doi: 10.1183/23120541.00625-2024. eCollection 2025 Mar.
2
SingleNucleotide Polymorphisms as Biomarkers of Mepolizumab and Benralizumab Treatment Response in Severe Eosinophilic Asthma.单核苷酸多态性作为美泊利珠单抗和贝那利珠单抗治疗重度嗜酸性粒细胞性哮喘应答的生物标志物。
Int J Mol Sci. 2024 Jul 26;25(15):8139. doi: 10.3390/ijms25158139.
3
Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study.
抗白细胞介素 5 治疗对严重未控制哮喘患者的影响及可能的反应预测生物标志物：一项真实世界研究。
Int J Mol Sci. 2023 Jan 19;24(3):2011. doi: 10.3390/ijms24032011.